點上方藍字“國際循環”關注我們，
然後點右上角“…”菜單，選擇“”
十一將至，11月還會遠嗎？
11月13日至15日，2021美國心臟協會科學年會（AHA 2021）線上召開，近日公布了7場 late-breaking science 會議內容。
《國際循環》編輯部為您整理如下。
LBS.01
心胸外科的瓣膜、靜脈和新觀點
Aortic Valve Replacement Versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: The Avatar Trial (AVATAR)
主動脈瓣置換術與無癥狀嚴重主動脈瓣狹窄的觀察等待：AVATAR試驗
Evaluating the Benefit of Concomitant Tricuspid Repair During Mitral Valve Surgery
評估二尖瓣手術合併三尖瓣修復的獲益
A Randomized Study of Early Versus Standard Coronary Artery Bypass Surgery Among Patients Presenting With Acute Coronary Syndromes Treated With Ticagrelor (RAPID CABG)
RAPID CABG：接受替格瑞洛治療的急性冠狀動脈綜合征患者早期與標準冠狀動脈搭橋手術的隨機研究
Efficacy and Safety of an External Support Device for Saphenous Vein Coronary Bypass Grafts: The VEST Trial (VEST)
一種大隱靜脈冠狀動脈旁路移植術外部支撐裝置的有效性和安全性：VEST試驗
LBS.02
高血壓：本地、全球和大流行的影響
A Remotely Delivered Hypertension and Lipid Program in 10,000 Patients Across a Diverse Health Care Network
通過多元化的醫療保健網絡，針對10,000名患者的遠程高血壓和血脂項目
Disruption in Blood Pressure Control With the Covid-19 Pandemic: A Study of 24 U.S. Health Systems in the PCORnet Blood Pressure Control Laboratory (BP Track)
BP Track：Covid-19大流行對血壓控制的破壞：PCORnet血壓控制實驗室對24 個美國衛生系統的研究
A Cluster Randomized Trial of a Village Doctor-Led Intervention on Blood Pressure Control: China Rural Hypertension Control Project (CRHCP)
鄉村醫生主導的干預血壓控制集群隨機試驗：中國農村高血壓控制項目（CRHCP）
LBS.03
房性心律失常的預防干預
The Coffee and Real-Time Atrial and Ventricular Ectopy (CRAVE) Trial (CRAVE)
咖啡和實時心房和心室異試驗( CRAVE )
Dabigatran Versus Warfarin on Cognitive Outcomes in Nonvalvular Atrial Fibrillation: Results of the GIRAF Trial. (GIRAF)
達比加群與華法林對非瓣膜性房顫認知結果的影響：GIRAF試驗結果。
Posterior Left Pericardiotomy Reduces Postoperative Atrial Fibrillation After Cardiac Surgery (PALACS)
左後心包切開術減少心臟手術後房顫( PALACS )
Outcomes of Adjunctive Left Atrial Appendage Ligation Utilizing the LARIAT Compared to Pulmonary Vein Antral Isolation Alone: The AMAZE Trial (AMAZE)
與單獨肺靜脈竇隔離相比，使用LARIAT輔助左心耳結紮術的結果：AMAZE試驗
LBS.04
信息超載？努力通過數字健康和自動化數據改善醫療服務
Risk Evaluation and its Impact on Clinical Decision-Making and Outcomes in Heart Failure: The REVeAL-HF Trial (REVeAL-HF)
心力衰竭風險評估及其對臨床決策和結果的影響：REVeAL-HF試驗
Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study
使用可穿戴設備檢測大量人群的心房顫動：Fitbit心臟研究
Testing Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib)
測試心房顫動的個體化觸發因素：一項隨機對照試驗( I-STOP-AFib )
LBS.05
以治療為基礎：心力衰竭治療的進展
Heart Failure With a Preserved Ejection Fraction ≥50% - Results From the EMPEROR-Preserved Clinical Trial (EMPEROR-Preserved)
射血分數≥50%的心力衰竭-來自EMPEROR-Preserved臨床試驗的結果
The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Clinical Trial (CHIEF-HF)
卡格列凈對心力衰竭患者健康狀況、生活質量和功能狀態的影響 (CHIEF-HF) 臨床試驗
Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial (EMPULSE)
恩格列凈在心力衰竭住院患者的療效和安全性：來自EMPULSE試驗的主要結果
Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients With Reduced Ejection Fraction (DREAM-HF)
射血分數降低的高危慢性心力衰竭患者經心內膜靶向輸送間充質前體細胞的隨機試驗( DREAM-HF )
LBS.06
魚油、可可和膽固醇：預防心血管疾病的食譜？
Icosapent Ethyl Versus Placebo in Outpatients With Covid-19: The Main Results of PREPARE-IT 2 (PREPARE-IT 2)
在Covid-19門診患者中使用Icosapent Ethyl與安慰劑：PREPARE-IT 2的主要結果
Primary Findings From the Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) on the Prevention of Cardiovascular Disease (COSMOS)
COSMOS：可可補充劑和多種維生素結果研究預防心血管疾病的主要發現
The Clinical Safety, Pharmacokinetics and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor
MK-0616（一種口服PCSK9抑製劑）的臨床安全性、葯代動力學和降低低密度脂蛋白膽固醇的療效
LBS.07
心血管疾病新葯及新葯適應證
Effects of Aspirin on Dementia and Cognitive Impairment in the ASCEND Trial (ASCEND)
在ASCEND試驗中阿司匹林對痴呆和認知障礙的影響
P2y12 Inhibitors in Noncritically Ill Hospitalized Patients With Covid-19 (ACTIV-4A)
ACTIV-4A：P2y12抑製劑在Covid-19非危重住院患者的應用
Effect Of Bentracimab on Platelet Inhibition and Hemostasis in Ticagrelor Patients With Uncontrolled Hemorrhage or Requiring Urgent Surgery in the REVERSE-IT (REVERSE-IT)
REVERSE-IT ：Bentracimab對替格瑞洛患者不可控出血或需要緊急手術的血小板抑制和止血的影響
Milvexian for Prevention of Venous Thromboembolism After Elective Knee Arthroplasty: The AXIOMATIC-TKR Study (AXIOMATIC-TKR)
Milvexian用於預防擇期膝關節置換術後靜脈血栓栓塞：AXIOMATIC-TKR研究
END
（來源：《國際循環》編輯部）
版
權
聲
明
凡原創文章版權屬《國際循環》所有。歡迎個人轉發分享。其他任何媒體、網站如需轉載或引用本網版權所有之內容須在醒目位置處註明“轉自《國際循環》”
點分享
點收藏
